Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase targeted drugs to treat inflammatory diseases. We are expanding our technology to address novel drug candidates for epigenetic targets in the complexes relevant to disease.
Latest News
- November 2009: Cellzome Advances Understanding of Hepatitis C [+]
Heidelberg, Germany, 23rd November 2009 - Cellzome announces that an article published today in Virology has shown that multiple cyclophilins - enzymes that facilitate protein folding - are involved in hepatitis C virus replication. The paper was published by scientists from Cellzome and Novartis Institutes of Biomedical Research (NIBR). In the study, two hepatitis C virus (HCV) drug candidates have been shown to interact with different cyclophilins and thus can attenuate viral replication. Interestingly, the different enzymes are found to participate in different cellular processes, the most prominent one being protein trafficking. full text [+]
- September 2009: Cellzome Announces Achievement of Fourth Milestone in Inflammation Alliance with GlaxoSmithKline [+]
Cambridge, UK and Heidelberg, Germany, 30th September 2009 - Cellzome Inc. announced today that it has successfully achieved the fourth milestone in its strategic alliance with GlaxoSmithKline. The achievement of this milestone triggers a further payment from GlaxoSmithKline. The amounts of these payments are undisclosed. full text [+]
- September 2009: Cellzome technology used to unravel novel regulatory mechanism in cancer signaling pathway [+]
Integrated chemical genetics and proteomics approach identifies new potential drug targets in Wnt pathway
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. full text [+]
Meet Cellzome at ... [+]